Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Intangibles (2016 - 2025)

Historic Intangibles for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $233.5 million.

  • Ligand Pharmaceuticals' Intangibles fell 1504.88% to $233.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.5 million, marking a year-over-year decrease of 1504.88%. This contributed to the annual value of $266.6 million for FY2024, which is 1100.04% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Intangibles is $233.5 million, which was down 1504.88% from $250.1 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Intangibles high stood at $583.8 million for Q1 2021, and its period low was $233.5 million during Q3 2025.
  • Moreover, its 5-year median value for Intangibles was $325.4 million (2023), whereas its average is $376.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Intangibles surged by 18267.72% in 2021, and later crashed by 3910.49% in 2023.
  • Ligand Pharmaceuticals' Intangibles (Quarter) stood at $376.7 million in 2021, then fell by 9.09% to $342.5 million in 2022, then dropped by 12.51% to $299.6 million in 2023, then dropped by 11.0% to $266.6 million in 2024, then decreased by 12.42% to $233.5 million in 2025.
  • Its last three reported values are $233.5 million in Q3 2025, $250.1 million for Q2 2025, and $258.4 million during Q1 2025.